Page 40 - ARNM-2-1

Advances in Radiotherapy
& Nuclear Medicine 99m Tc-DOX in multidrug resistance studies

41. Muzzammil T, Moore MJ, Hedley D, Ballinger JR. systems and intact cells. Cancer Res. 1976;36(8):2891-2895.
Comparison of (99m)Tc-sestamibi and doxorubicin to 49. Polyak A, Palade EA, Balogh L, et al. In vitro and
monitor inhibition of P-glycoprotein function. Br J Cancer.
2001;84(3):367-373. biodistribution examinations of Tc-99m-labelled
doxorubicin-loaded nanoparticles. Nucl Med Rev Cent East
doi: 10.1054/bjoc.2000.1621 Eur. 2011;14(2):55-62.
42. Ohtani H, Ikegawa T, Honda Y, et al. Effects of various doi: 10.5603/nmr.2011.00016
methoxyflavones on vincristine uptake and multidrug
resistance to vincristine in P-gp-overexpressing K562/ADM 50. Bao A, Goins B, Klipper R, Negrete G, Phillips WT. Direct
cells. Pharm Res. 2007;24(10):1936-1943. 99m Tc labeling of pegylated liposomal doxorubicin (Doxil)
for pharmacokinetic and non-invasive imaging studies.
doi: 10.1007/s11095-007-9320-6 Pharmacology. 2004;308(2):419-425.
43. Mezi S, Primi F, Capoccetti F, Scopinaro F, Modesti M, doi: 10.1124/jpet.103.059535
Schillaci O. In vivo detection of resistance to anthracycline
based neoadjuvant chemotherapy in locally advanced and 51. Sun H, Sloan A, Mangner TJ, et al. Imaging DNA synthesis
inflammatory breast cancer with technetium-99m sestamibi with [18F]FMAU and positron emission tomography
scintimammography. Int J Oncol. 2003;22(6):1233-1240. in patients with cancer. Eur J Nucl Med Mol Imaging.
2005;32(1):15-22.
44. Kostakoglu L. Noninvasive detection of multidrug resistance
in patients with hematological malignancies: Are we there doi: 10.1007/s00259-004-1713-8
yet? Clin Lymphoma. 2002;2(4):242-248. 52. Koukourakis MI, Koukouraki S, Fezoulidis I, et al.
®
doi: 10.3816/clm.2002.n.006 High intratumoural accumulation of stealth liposomal
doxorubicin (Caelyx®) in glioblastomas and in metastatic
45. Solbach C, Patt M, Reimold M, et al. [11 C]Vinblastine brain tumours. Br J Cancer. 2000;83(10):1281-1286.
syntheses and preliminary imaging in cancer patients.
J Pharm Pharm Sci. 2007;10(2):266s-76s. doi: 10.1054/bjoc.2000.1459
46. Kurdziel KA, Kiesewetter DO. PET imaging of multidrug 53. Kumar P, Singh B, Sharma S, et al. Preclinical evaluation of
resistance in tumors using 18F-fluoropaclitaxel. Curr Top [99m]Tc-Labeled doxorubicin as a potential scintigraphic
Med Chem. 2010;10(17):1792-1798. probe for tumor imaging. Cancer Biother Radiopharm.
2012;27(3):221-225.
doi: 10.2174/156802610792928077
doi: 10.1089/cbr.2011.1086
47. Fornari FA, Randolph JK, Yalowich JC, Ritke MK, Gewirtz DA.
Interference by doxorubicin with DNA unwinding in 54. Yang FY, Wang HE, Liu RS, et al. Pharmacokinetic
MCF-7 breast tumor cells. Mol Pharmacol. 1994;45(4): analysis of 111In-labeled liposomal doxorubicin in murine
649-656. glioblastoma after blood-brain barrier disruption by focused
ultrasound. PLoS One. 2012;7(9):e45468.
48. Momparler RL, Karon M, Siegel SE, Avila F. Effect of
adriamycin on DNA, RNA, and protein synthesis in cell-free doi: 10.1371/journal.pone.0045468

Volume 2 Issue 1 (2024) 9 https://doi.org/10.36922/arnm.2822